| Company | Value | Change | %Change |
|---|
INQ Holding LLC, SmallCap World Fund Inc, Fidelity Funds, Abu Dhabi Investment Authority, Goldman Sachs Funds, BlackRock, Nippon India Mutual Fund (MF), HDFC MF, Axis MF and Kotak Mahindra MF are among the anchor investors, according to a circular uploaded on the BSE website.
According to the circular, Sai Life Sciences has allotted more than 1.66 crore equity shares to 63 funds at ₹549 apiece, which is also the upper end of the price band. This takes the transaction size to ₹913 crore.
The ₹3,043-crore IPO will open for public subscription on Wednesday and conclude on Friday.
The price band for the issue has been fixed at ₹522 to ₹549 apiece.
The proposed IPO comprises fresh issue of equity shares worth ₹950 crore and an offer for sale (OFS) of 3.81 crore shares valued ₹2,092 crore, at the upper end of the price band, by a promoter, investor shareholders and other shareholders.
Under the OFS, one of the promoter entities — Sai Quest Syn Private Limited — and investor shareholders — TPG Asia VII SF Pte Ltd, HBM Private Equity India — will partly offload their respective stakes.
At present, Sai Quest Syn holds a 5.61% stake in the company, TPG owns 39.69%, and HBM Private Equity India 5.5%.
Of the IPO proceeds, funds to the tune of ₹600 crore will be used for debt payment and a portion for corporate general purposes.
The Hyderabad-based Sai Life Sciences provides end-to-end services across the drug discovery, development and manufacturing value chain for small molecule new chemical entities (NCE) to global pharmaceutical innovator companies and biotechnology firms.
According to the F&S report, the India CRDMO market (contract research, development and manufacturing organisation) was among the fastest growing in the APAC during 2018-2023.
This growth is expected to continue, with the Indian market projected to grow 14% between 2023 and 2028, reaching an estimated value of $14.1 billion in 2028.
Kotak Mahindra Capital Company, IIFL Securities, Jefferies India Private Limited and Morgan Stanley India Company Private Limited are the book-running lead managers for the company’s IPO.
